Skip to main content

Neoadjuvant immunotherapy in melanoma: the future is now

Intervista a Georgina Long By 4 Dicembre 2023No Comments
Congressi

In this time of melanoma history neoadjuvant immunotherapy is rapidly becoming a standard treatment. But what wll we see in the next future? We asked Georgina Long (Co-Medical Director of Melanoma Institute Australia – MIA, Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney) that we met at Melanoma Bridge congress 2023 in Naples.